-
Product Insights
New![]()
Net Present Value Model: Alnylam Pharmaceuticals Inc’s Zilebesiran
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Alnylam Pharmaceuticals Inc – Company Profile
Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis, Givlaari for acute hepatic porphyria, Amvuttra, for the treatment of ATTR amyloidosis with cardiomyopathy, and Oxlumo for primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi drugs in the areas of genetic medicines, hepatic infectious,...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s EBI-031
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewAmyloidosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Amyloidosis Clinical Trials Market Report Overview The Amyloidosis clinical trial market research report provides an overview of the Amyloidosis clinical trials scenario. This report provides top-line data relating to the clinical trials on Amyloidosis and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It provides prominent drugs...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cemdisiran in IgA Nephropathy (Berger’s Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Cemdisiran in IgA Nephropathy (Berger's Disease) Drug Details: Cemdisiran is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rapirosiran Sodium in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Rapirosiran Sodium in Non-Alcoholic Steatohepatitis (NASH)Drug Details:Rapirosiran (ALN-HSD) is under development for the treatment of non-alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ALNTTRSC-04 in Amyloidosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ALNTTRSC-04 in AmyloidosisDrug Details:ALNTTRSC-04 is under development for the treatment of ATTR amyloidosis. It is administered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ALN-PNP in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ALN-PNP in Non-Alcoholic Steatohepatitis (NASH)Drug Details:ALN-PNP is under development for the treatment of non-alcoholic steatohepatitis (NASH)....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EO-2463 in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EO-2463 in Marginal Zone B-cell Lymphoma Drug Details: EO-2463 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Cemdisiran is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cemdisiran in Hematuria
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cemdisiran in Hematuria Drug Details: Cemdisiran is under development for the treatment of IgA nephropathy,...
-
Sector Analysis
NewJuvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Overview JMD, also called juvenile macular dystrophy, is a group of inherited eye disorders that affects children and young adults, disturbing their central vision. JMD is classified into three major types: Stargardt disease, X-linked retinoschisis (juvenile retinoschisis), and Best vitelliform macular dystrophy (Best’s disease). In the 16MM (Australia, Brazil, China, Canada, France, Germany, India, Italy, Japan, Mexico, Russia, South Africa, South Korea, Spain, UK, and the US), epidemiologists estimate there were around...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zilebesiran Sodium in Hypertension
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilebesiran Sodium in Hypertension Drug Details: Zilebesiran sodium (ALNAGT-01) is under development for hypertension. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GMCN-508A in Alpha Thalassaemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GMCN-508A in Alpha Thalassaemia Drug Details: GMCN-508A is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ALN-APP in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ALN-APP in Alzheimer's Disease Drug Details:ALN-APP is under development for the treatment of  Alzheimer’s Disease, cerebral...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sovilnesib in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Sovilnesib in Solid Tumor Drug Details:Sovilnesib (AMG-650) is under development for the treatment of triple-negative breast...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMX-3009 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMX-3009 in Solid Tumor Drug Details: AMX-3009 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vutrisiran in Familial Amyloid Cardiomyopathy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Vutrisiran in Familial Amyloid Cardiomyopathy Drug Details: Vutrisiran (Amvuttra) is designed to target and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADG-126 in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ADG-126 in Triple-Negative Breast Cancer (TNBC) Drug Details:ADG-126 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Patisiran in Familial Amyloid Cardiomyopathy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Patisiran in Familial Amyloid Cardiomyopathy Drug Details: Patisiran (Onpattro) is a oligonucleotide. It is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.